Excipients and Their Role in Approved Injectable Products: Current Usage and Future Directions

References

1. 1.↵
   1. Robertson M. I.

   Regulatory issues with excipients. Int. J. Pharm. 1999, 187, 273–276.

   OpenUrlPubMed
2. 2.↵
   1. Amidon G. E.,
   2. Peck G. E.,
   3. Block L. H.,
   4. Moreton R. C.,
   5. Katdare A.,
   6. Lafaver R.,
   7. Sheehan C.

   〈1059〉 Excipient performance, a proposed new USP General Information Chapter. Pharmacopoeial Forum 2007, 33 (6), 1311–1321.

   OpenUrl
3. 3.↵
   1. Moreton C.

   Functionality and performance of excipients in a quality-by-design world: Part 1. Am. Pharm. Rev. 2009, 12 (1), 40–44.

   OpenUrl
4. 4.↵
   Industry is developing a more profound understanding of excipients. Gold Sheet 2009, September.
5. 5.↵
   BP. Parenteral Preparations. In British Pharmacopoeia, Stationary Office: London, 1999; Vol. II, p 1575.

   OpenUrl
6. 6.↵
   EP. Parenteral Preparations. In European Pharmacopoeia, 6 ed.; Council of Europe: Strasbourg, 2009; p 1765.
7. 7.↵
   1. Uchiyama M.

   Regulatory status of excipients in Japan. Drug Information Journal 1999, 33 (1), 27–32.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Avis K. E.,
   2. Lieberman H. A.,
   3. Lachman L.

   1. Boylan J. C.,
   2. DeLuca P. P.

   Formulation of Small Volume Parenterals. In Pharmaceutical Dosage Forms: Parenteral Medications, 2nd ed.; Avis K. E., Lieberman H. A., Lachman L. Eds. Marcel Dekker, Inc.: New York, 1992; Vol. 1, pp 173–248.

   OpenUrl
9. 9.↵
   1. Matthews B.

   Excipients used in products approved through the E.U. centralised procedure. The Regulatory Affairs J. 2002, 13 (12), 1036–1044.

   OpenUrl
10. 10.↵
    1. Matthews B.

    Excipients for non-oral routes of administration. The Regulatory Affairs J. 2002, 13 (11), 897–908.

    OpenUrl
11. 11.↵
    1. Nema S.,
    2. Washkuhn R. J.,
    3. Brendel R. J.

    Excipients and their use in injectable products. PDA J. Pharm. Sci. Technol. 1997, 51 (4), 166–171.

    OpenUrlAbstract/FREE Full Text
12. 12.↵
    1. Powell M. F.,
    2. Nguyen T.,
    3. Baloian L.

    Compendium of excipients for parenteral formulations. PDA J. Pharm. Sci. Technol. 1998, 52 (5), 236–311.

    OpenUrlFREE Full Text
13. 13.↵
    1. Strickley R. G.

    Parenteral formulations of small molecules therapeutics marketed in the United States (1999). Part I. PDA J. Pharm. Sci. Technol. 1999, 53 (6), 324–349.

    OpenUrlFREE Full Text
14. 14.↵
    1. Strickley R. G.

    Parenteral formulations of small molecules therapeutics marketed in the United States (1999). Part II. PDA J. Pharm. Sci. Technol. 2000, 54 (1), 69–96.

    OpenUrlFREE Full Text
15. 15.↵
    1. Strickley R. G.

    Parenteral formulations of small molecules therapeutics marketed in the United States (1999). Part III. PDA J. Pharm. Sci. Technol. 2000, 54 (2), 152–169.

    OpenUrlFREE Full Text
16. 16.↵
    1. Wang Y. J.,
    2. Hanson M. A.

    Parenteral formulations of proteins and peptides: stability and stabilizers. PDA Pharm. J. Sci. Technol. 1988, 42 supplement, S4–S26.

    OpenUrl
17. 17.↵
    1. Wang Y. J.,
    2. Kowal R. R.

    Review of excipients and pH's for parenteral products used in the United States. J. Parenter. Sci. Technol. 1980, 34 (6), 452.

    OpenUrl
18. 18.↵
    GenRx. Mosby's GenRx, 8 ed.; Mosby-Year Book, Inc.: St. Louis, 1998.
19. 19.↵
    Physician's Desk Reference, 63 ed.; Thomson Corporation: Toronto, 2009.
20. 20.↵
    FDA. Inactive Ingredient Guide. In Division of Drug Information Resources; FDA, CDER: 2009.
21. 21.↵
    1. Rowe R. C.,
    2. Sheskey P. J.,
    3. Quinn M. E.

    Handbook of Pharmaceutical Excipients, 6 ed.; The Pharmaceutical Press: London, 2009.
22. 22.↵
    1. Trissel L. A.

    Handbook on Injectable Drugs, 10 ed.; American Society of Health-System Pharmacists, Inc: Bethesda, MD, 1998.
23. 23.↵
    EMEA. Note for Guidance on Quality of Water for Pharmaceutical Use. In CPMP/QWP/158/01 revision—EMEA/CVMP/115/01 revision: May 2002.
24. 24.↵
    EMEA. Reflection Paper on Water for Injection Prepared by Reverse Osmosis. In EMEA/CHMP/CVMP/QWP/28271/2008: 5 March 2008.
25. 25.↵
    1. Sweetana S.,
    2. Akers M. J.

    Solubility principles and practices for parenteral drug dosage form development. PDA J. Pharm. Sci. Technol. 1996, 50 (5), 330–342.

    OpenUrlFREE Full Text
26. 26.↵
    1. Yalkowsky S. H.,
    2. Roseman T. J.

    Solubilization of Drugs by Cosolvents. In Techniques of Solubilization of Drugs; Marcel Dekker, Inc.: New York, 1981; pp 91–134.
27. 27.↵
    1. Hancock B. C.,
    2. York P.,
    3. Rowe R. C.

    The use of solubility parameters in pharmaceutical dosage form design. Int. J. Pharm. 1997, 148, 1–21.

    OpenUrl
28. 28.↵
    1. Rubino J. T.,
    2. Yalkowsky S. H.

    Cosolvency and cosolvent polarity. Pharm. Res. 1987, 4 (3), 220–230.

    OpenUrlPubMed
29. 29.↵
    1. Brazeau G. A.,
    2. Cooper B.,
    3. Svetic K. A.,
    4. Smith C. L.,
    5. Gupta P.

    Current perspectives on pain upon injection of drugs. J. Pharm. Sci. 1998, 87 (6), 667–677.

    OpenUrlCrossRefPubMedWeb of Science
30. 30.↵
    1. Brazeau G. A.,
    2. Fung H.

    Use of an in vivo model for the assessment of muscle damage from intramuscular injections: in vitro–in vivo correlation and predictability with mixed solvent systems. Pharm. Res. 1989, 6 (9), 766–771.

    OpenUrlCrossRefPubMedWeb of Science
31. 31.↵
    1. Reed K. W.,
    2. Yalkowsky S.

    Lysis of human red blood cells in the presence of various cosolvents. J. Parenter. Sci. Technol. 1985, 39 (2), 64–69.

    OpenUrlPubMed
32. 32.↵
    1. Yalkowsky S. H.,
    2. Krzyzaniak J. F.,
    3. Ward G. H.

    Formulation-related problems associated with intravenous drug delivery. J. Pharm. Sci. 1998, 87 (7) 787–796.

    OpenUrlCrossRefPubMedWeb of Science
33. 33.↵
    1. Mottu F.,
    2. Laurent A.,
    3. Rufenacht D. A.,
    4. Doelker E.

    Organic solvents for pharmaceutical parenterals and embolic liquids: a review of toxicity data. PDA J. Pharm. Sci. Technol. 2000, 54 (6), 456–465.

    OpenUrlAbstract/FREE Full Text
34. 34.↵
    USP. 〈1〉 Injections. In USP, 32 ed.; U.S. Pharmacopeial Convention, Inc.: Rockville, MD, 2009.
35. 35.↵
    JP. Injections. In The Japanese Pharmacopoeia, XV ed.; 2006, p 10.
36. 36.↵
    1. Johnson D. M.,
    2. Gu L. C.

    Autoxidation and Antioxidants. In Encyclopedia of Pharmaceutical Technology; Swarbrick, J.; Boylan, J. C., Eds. Marcel Dekker, Inc.: New York, 1988; Vol. 1 , pp 415–449.

    OpenUrl
37. 37.↵
    1. Pearlman R.,
    2. Wang Y. J.

    1. Herman A. C.,
    2. Boone T. C.,
    3. Lu H. S.

    Characterization, Formulation, and Stability of Neupogen (Filgrastim), a Recombinant Human Granulocyte-Colony Stimulating Factor. In Formulation, Characterization, and Stability of Protein Drugs: Case Histories; Pearlman R., Wang Y. J. Eds. Plenum Press: New York, 1996; Vol. 9, p 325.

    OpenUrl
38. 38.↵
    1. Fatouros A.,
    2. Osterberg T.,
    3. Mikaelsson M.

    Recombinant factor VIII SQ—influence of oxygen, metal ions, pH and ionic strength on its stability in aqueous solution. Int. J. Pharm. 1997, 155 (1), 121–131.

    OpenUrlCrossRefWeb of Science
39. 39.↵
    1. Stadtman E. R.

    Metal ion-catalyzed oxidation of proteins: biochemical mechanism and biological consequences. Free Radical Biol. Med. 1990, 9 (4), 315–325.

    OpenUrlCrossRefPubMedWeb of Science
40. 40.↵
    1. Enever R. P.,
    2. Po A. L. W.,
    3. Shotton E.

    Factors influencing decomposition rate of amitriptyline hydrochloride in aqueous solution. J. Pharm. Sci. 1977, 66 (8), 1087–1089.

    OpenUrlPubMed
41. 41.↵
    1. Munson J. W.,
    2. Hussain A.,
    3. Bilous R.

    Precautionary note for use of bisulfite in pharmaceutical formulations. J. Pharm. Sci. 1977, 66 (12), 1775–1776.

    OpenUrlPubMed
42. 42.↵
    1. Akers M. J.

    Antioxidants in pharmaceutical products. J. Parenter. Sci. Technol. 1982, 36 (5), 222–228.

    OpenUrlPubMed
43. 43.↵
    Committee for Proprietary Medicinal Products (CPMP). Note for Guidance on inclusion of Antioxidants and Antimicrobial Preservatives in Medicinal Products. In CPMP: January 1998.
44. 44.↵
    EMEA. Guideline on Excipients in the Dossier for Application for Marketing Authorization of a Medical Product. In EMEA/CHMP/QWP/396951/2006: 19 June 2007.
45. 45.↵
    1. Dabbah R.

    The use of preservatives in compendial articles. Pharmacopeial Forum 1996, 22 (4), 2696.

    OpenUrl
46. 46.↵
    Martindale: The Extra Pharmacopoeia. 31 ed.; Royal Pharmaceutical Society: London, 1996; p 1128.
47. 47.↵
    British Pharmaceutical Codex, Royal Pharmaceutical Society: London, 1973. p 100.
48. 48.↵
    1. Oishi S.

    Effects of propyl paraben on the male reproductive system. Food Chem. Toxicol. 2002, 40 (12), 1807–1813.

    OpenUrlCrossRefPubMedWeb of Science
49. 49.↵
    1. Oishi S.

    Effects of butylparaben on the male reproductive system in mice. Arch. Toxicol. 2002, 76 (7), 423–429.

    OpenUrlCrossRefPubMedWeb of Science
50. 50.↵
    1. Oishi S.

    Lack of spermatotoxic effects of methyl and ethyl esters of p-hydroxybenzoic acid in rats. Food Chem. Toxicol. 2004, 42, 1845–1849.

    OpenUrlCrossRefPubMedWeb of Science
51. 51.↵
    1. Hoberman A. M.,
    2. Schreur D. K.,
    3. Leazar T.,
    4. Daston D. P.,
    5. Carthew P.,
    6. Re T.,
    7. Loretz L.,
    8. Mann P.

    Lack of effect of butylparaben and methylparabben on the reproductive system in male rats. Birth Defects Res. B Dev. Reprod. Toxicol. 2008, 83 (2), 123–133.

    OpenUrlCrossRefPubMedWeb of Science
52. 52.↵
    1. Dabbah R.

    Harmonization of microbiological methods—a status report. Pharmacopeial Forum 1997, 23 (6), 5334–5344.

    OpenUrl
53. 53.↵
    European Pharmacopoeia, 3 ed.; Council of Europe: Strasbourg, 1997; p 286.
54. 54.↵
    USP. 〈51〉 Antimicrobial Effectiveness Testing. In USP, 32 ed.; U.S. Pharmacopeial Convention, Inc.: Rockville, MD, 2009.
55. 55.↵
    CPMP. Note for Guidance on Maximum Shelf-life for Sterile Products for Human Use After First Opening or Following Reconstitution. CPMP, July 1998.
56. 56.↵
    1. Lam X. M.,
    2. Costantino H. R.,
    3. Overcashier D. E.,
    4. Nguyen T. H.,
    5. Hsu C. C.

    Replacing succinate with glycolate buffer improves the stability of lyophilized interferon-gamma. Int. J. Pharm. 1996, 142 (1), 85–95.

    OpenUrl
57. 57.↵
    1. Piedmonte D. M.,
    2. Summers C.,
    3. McAuley A.,
    4. Karamujic L.,
    5. Ratnaswamy G.

    Sorbitol crystallization can lead to protein aggregation in frozen protein formulations. Pharm. Res. 2007, 24 (1), 136–146.

    OpenUrlPubMed
58. 58.↵
    1. Pikal M. J.

    The Correlation of Structural Relaxation Time with Pharmaceutical Stability. Freeze-Drying of Pharmaceuticals and Biologicals Conference, Brownsville, VT, September 23–26, 1998.
59. 59.↵
    1. Arakawa T.,
    2. Kita Y.,
    3. Carpenter J. F.

    Protein-solvent interactions in pharmaceutical formulations. Pharm. Res. 1991, 8 (3), 285–291.

    OpenUrlPubMed
60. 60.↵
    1. Miller D. P.,
    2. Anderson R. E.,
    3. de Pablo J. J.

    Stabilization of lactate dehydrogenase following freeze-thawing and vacuum-drying in the presence of trehalose and borate. Pharm. Res. 1998, 15 (8), 1215–1221.

    OpenUrlCrossRefPubMedWeb of Science
61. 61.↵
    1. Carpenter J. F.,
    2. Crowe J. H.

    Modes of stabilization of a protein by organic solutes during desiccation. Cryobiology 1998, 25 (5), 459–470.

    OpenUrl
62. 62.↵
    1. Baumann T. J.,
    2. Smythe M. A.,
    3. Kaufmann K.,
    4. Miloboszewski Z.,
    5. O'Malley J.,
    6. Fudge R. P.

    Dissolution times of adriamycin and adriamycin RDF. Am. J. Hosp. Pharm. 1988, 45, 1667.

    OpenUrl
63. 63.↵
    1. Jain N. K.,
    2. Jain S.,
    3. Singhai A. K.

    Enhanced solubilization and formulation of an aqueous injection of piroxicam. Pharmazie 1997, 52 (12), 942–946.

    OpenUrl
64. 64.↵
    1. Meyer J. D.,
    2. Manning M. C.

    Hydrophobic ion pairing: altering the solubility properties of biomolecules. Pharm. Res. 1998, 15 (2), 188–192.

    OpenUrlCrossRefPubMed
65. 65.↵
    1. Wang Y. J.,
    2. Dahl T. C.,
    3. Leesman G. D.,
    4. Monkhouse D. C.

    Optimization of autoclave cycles and selection of formulation for parenteral product. Part II: Effect of counter-ion on pH and stability of diatrizoic acid at autoclave temperatures. J. Parenter. Sci. Technol. 1984, 38 (2), 72–77.

    OpenUrlPubMed
66. 66.↵
    JPE. Japanese Pharmaceutical Excipients Directory. Yakuji Nippo, Ltd: Tokyo, 2004.
67. 67.↵
    Excipients in Pharmaceutical Dosage Forms: The Challenge of the 21st Century. Nice, France, May 14–15, 1998.
68. 68.↵
    PF. Benzyl alcohol. Pharmacopeial Forum 1995, 21 (5).
69. 69.↵
    USP. 〈1078〉 Good Manufacturing Practices for Bulk Pharmaceutical Excipients. In USP, 32nd ed.; U.S. Pharmacopeial Convention, Inc.: Rockville, MD, 2009.
70. 70.↵
    Excipients in the Label and Package Leaflet of Medicinal Products for Human Use. In European Commission; July 2003; Guidelines Medicinal products for human use Safety, environment and information Vol. 3B.
71. 71.↵
    CPMP. Note for Guidance on the Use of Bovine Serum in the Manufacture of Human Biological Medicinal Products. In CPMP/BWP/1793/02: 18 June 2003.
72. 72.↵
    CPMP. Note for Guidance on Development Pharmaceutics. In CPMP: July 1998.
73. 73.↵
    1. Akers M. J.

    Excipient-drug interactions in parenteral formulations. J. Pharm. Sci. 2002, 91 (11), 2283–2300.

    OpenUrlCrossRefPubMed
74. 74.↵
    1. Paul W. L.

    Excipient intake and heavy metals limits. Pharmacopeial Forum 1995, 21 (6), 1638–1640.

    OpenUrl
75. 75.↵
    Aluminum in large and small volume parenterals used in total parenteral nutrition. Federal Register 1998, 63 (2), 176–185.

    OpenUrlPubMed
76. 76.↵
    FDA. Guideline on Validation of the Limulus Amebocyte Lysate Test as an End-Product Test for Human and Animal Parenteral Drugs. In Biological Products and Medical Devices, FDA: December 1987.
77. 77.↵
    1. Opalchenova G. A.

    Comparison of the microbial limit tests in the British, European, and United States Pharmacopeias and recommendation for harmonization. Pharmacopeial Forum 1994, 20 (4), 7872–7877.

    OpenUrl
78. 78.↵
    1. Taylor P.

    Regulation for excipients is brewing across the Atlantic. Pharm. Technol. 2009, 33 (2), 86–87.

    OpenUrl
79. 79.↵
    Fatalities Associated with Ingestion of Diethylene Glycol-Contaminated Glycerin Used to Manufacture Acetaminophen Syrup—Haiti, November 1995–June 1996, In Morbidity and Mortality Weekly Report, U.S. Department of Health and Human Services: August 2, 1996; Vol. 45, pp 649–650.

    OpenUrlPubMed
80. 80.↵
    FDA. Pharmaceutical Components at Risk for Melamine Contamination. U.S. Department of Health and Human Services, FDA.; August 2009.
81. 81.↵
    FDA. Interim Inactive Ingredient Policy. Office of Generic Drugs (OGD), FDA, 1994.
82. 82.↵
    1. Weiner M.,
    2. Bernstein I. L.

    Adverse Reactions to Drug Formulation Agents: A Handbook of Excipients, Marcel Dekker, Inc: New York, NY, 1989.
83. 83.↵
    USP. 〈1074〉 Excipient Biological Safety Evaluation Guidelines. In USP, 32 ed.; U.S. Pharmacopeial Convention, Inc: Rockville, MD, 2009.
84. 84.↵
    FDA. Nonclinical Studies for the Safety Evaluation of Pharmaceutical Excipients. Guidance for Industry; FDA; May 2005.
85. 85.↵
    1. Matthews B.

    BSE/TSE risks associated with active pharmaceutical ingredients and starting materials: the situation in Europe and the global implications for healthcare manufacturers. PDA J. Pharm. Sci. Technol. 2001, 55 (5), 295–328.

    OpenUrlFREE Full Text
86. 86.↵
    CPMP. Note for Guidance on Minimizing the Risk of Transmitting Animal Spongiform Encephalopathy Agents via Medicinal Products. In CPMP: 21 April 1999.
87. 87.↵
    FDA. The Sourcing and Processing of Gelatin to Reduce the Potential Risk Posed by Bovine Spongiform Encephalopathy (BSE) in FDA-Regulated Products for Human Use. Guidance for Industry. U.S. Department of Health and Human Services, FDA: September 1997.
88. 88.↵
    EMEA. Gelatin for Use in Pharmaceuticals: Explanatory Note. In EMEA/CPMP/4306/00/v0.2: 13 December 2000.
89. 89.↵
    EMEA. First Cases of BSE in USA and Canada: Risk Assessment of Ruminate Materials Originating from USA and Canada. In EMEA/CHMP/BWP/27/04: 21 July 2004.
90. 90.↵
    EMEA. CHMP Position Statement on Creutzfeldt-Jakob Disease and Plasma-Derived and Urine Derived Medicinal Products. In EMEA/CPMP/BWP/2879/02/rev 1: 23 June 2004.
91. 91.↵
    1. Chuang V. T. G.,
    2. Kragh-Hansen U.,
    3. Otagiri M.

    Pharmaceutical strategies utilizing recombinant human serum albumin. Pharm. Res. 2002, 19 (5).
92. 92.↵
    CPMP. Position State on Polysorbate 80. In CPMP/BWP/1952/98: 22 October 1998.
93. 93.↵
    1. Frank D. W.,
    2. Gray J. E.,
    3. Weaver R. N.

    Cyclodextrin nephrosis in the rat. Am. J. Pathol. 1976, 83 (2) 367–382.

    OpenUrlPubMedWeb of Science
94. 94.↵
    1. Stella V. J.,
    2. Rajewski R. A.

    Cyclodextrins: their future in drug formulation and delivery. Pharm. Res. 1997, 14 (5), 556–567.

    OpenUrlCrossRefPubMedWeb of Science
95. 95.↵
    1. Thompson D. O.

    Cyclodextrins—enabling excipients: their present and future use in pharmaceuticals. Crit. Rev. Ther. Drug Carrier Sys. 1997, 14 (1), 1–104.

    OpenUrlPubMedWeb of Science
96. 96.↵
    1. Loftsson T.,
    2. Johannesson H. R.

    The influence of cyclodextrins on the stability of cephalothin and aztreonam in aqueous solutions. Die Pharmazie 1994, 49, 292–293.

    OpenUrl
97. 97.↵
    1. Lehner S. J.,
    2. Muller B. W.,
    3. Seydel J. K.

    Effect of hydroxylpropyl-beta-cyclodextrin on the antimicrobial action of preservatives. J. Pharm. Pharmacol. 1994, 46 186–191.

    OpenUrlPubMed
98. 98.↵
    1. Felt O.,
    2. Buri P.,
    3. Gurny R.

    Chitosan: A unique polysaccharide for drug delivery. Drug Dev. Ind. Pharm. 1998, 24 (11), 979–993.

    OpenUrlPubMed
99. 99.↵
    1. Jain R.,
    2. Shah N. H.,
    3. Malick A. W.,
    4. Rhodes C. T.

    Controlled drug delivery by biodegradable poly(ester) devices: different preparative approaches. Drug Dev. Ind. Pharm. 1998, 24 (8), 703–727.

    OpenUrlPubMed
100. 100.↵
     1. Middleton J. C.,
     2. Tipton A. J.

     Synthetic biodegradable polymers as medical devices. Medical Plastics Biomaterials 1998, 5 (2) 30–39.

     OpenUrl
101. 101.↵
     1. Pettit D. K.,
     2. Lawter J. R.,
     3. Huang W. J.,
     4. Pankey S. C.,
     5. Nightlinger N. S.,
     6. Lynch D. H.,
     7. Schuh J. A. C. L.,
     8. Morrissey P. J.,
     9. Gombotz W. R.

     Characterization of poly(glycolide-co-D,L-lactide)/poly(D,L-lactide) microspheres for controlled release of GM-CSF. Pharm. Res. 1997, 14 (10), 1422–1430.

     OpenUrlCrossRefPubMed
102. 102.↵
     1. Katre N. V.,
     2. Asherman J.,
     3. Schaefer H.

     Multivesicular liposome (DepoFoam™) technology for the sustained delivery of Insulin-like Growth Factor—I. J. Pharm. Sci. 1998, 87 (11), 1341–1346.

     OpenUrlPubMed
103. 103.↵
     1. Wang P.,
     2. Johnston T. P.

     Sustained-release Interleukin-2 following intramuscular injection in Rats. Int. J. Pharm. 1995, 113 (1), 73–81.

     OpenUrl
104. 104.↵
     1. Moghimi S. M.

     mechanisms regulating body distribution of nanospheres conditioned with pluronic and tetronic block co-polymers. Adv. Drug Deliv. Rev. 1995, 16 (2–3), 183–193.

     OpenUrl
105. 105.↵
     1. Zheng J. Y.,
     2. Bosch H. W.

     Sterile filtration of NanoCrystal™ drug formulations. Drug Dev. Ind. Pharm. 1997, 23 (11), 1087–1093.

     OpenUrl
106. 106.↵
     1. Knepp V. M.,
     2. Muchnik A.,
     3. Oldmark S.,
     4. Kalashnikova L.

     Stability of non-aqueous suspension formulations of plasma-derived factor IX and recombinant human alpha interferon at elevated temperatures. Pharm. Res. 1998, 15 (7), 1090–1095.

     OpenUrlPubMed
107. 107.↵
     1. Sullivan S. A.,
     2. Gilley R. M.,
     3. Gibson J. W.,
     4. Tipton A. J.

     Delivery of taxol and other antineoplastic agents from a novel system based on sucrose acetate isobutyrate. Pharm. Res. 1997, 14 (11), 291.

     OpenUrl
108. 108.↵
     1. Gombotz W. R.,
     2. Pettit D. K.

     Biodegradable polymers for proteins and peptide drug delivery. Bioconjug. Chem. 1995, 6 (4), 332–351.

     OpenUrlCrossRefPubMedWeb of Science
109. 109.↵
     1. Apte S. R.,
     2. Ogwu S. O.

     A review and classification of emerging excipients in parenteral medications. Pharm. Technol. 2003, 27 (3), 46–60.

     OpenUrl